Pharmafile Logo

News and Press Releases

FLAMOD against respiratory infections: phase I clinical trial of innovative new drug begins

20 March 2025 -- Lausanne, Switzerland -- A phase I clinical trial for a groundbreaking therapeutic innovation against respiratory infections has begun at the Clinical Investigation Centre of the Academic...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

European Respiratory Society
4, Avenue Ste-Luce CH 1003 Lausanne Switzerland

Carbon Minimal pressurised Metered Dose Inhalers (pMDIs) could save up to 619,000 tonnes of emissions each year, representing up to 7%-10% of NHS Net Zero targets

At a national level, seamless transitioning to a range of carbon minimal pMDIs could save between 415,000 and 619,000 tCO₂e annually, reducing carbon emissions to the equivalent financial value of...

Category: Drug Delivery, Manufacturing and Packing
Posted: March 10, 2025

Chiesi
info@chiesi.uk.com
333 Styal Road Manchester M22 5LG United Kingdom

ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051

10 February 2025 -- Melbourne, Australia -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it...

Category: Biotechnology, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: February 10, 2025

ENA Respiratory

Coveris MediFlex – a strong brand for medical packaging

11 November 2024 – Vienna, Austria – Following extensive investments in its medical production facilities, Coveris is now consolidating its capabilities and high-class medical offerings under one brand name: MediFlex....

Category: Manufacturing and Packing
Posted: November 18, 2024

Coveris
Coveris Management GmbH, Wienerbergstraße 11, A28, 1100 Vienna, Austria

Bespak and Orbia Fluor & Energy Materials unite to accelerate transition to climate-friendly inhalers

Collaboration aims to speed the commercialisation of low global warming potential pMDIs utilising Orbia Fluor & Energy Materials’ Zephex® 152a propellant at Bespak’s Holmes Chapel site 6 November 2024 –...

Category: Drug Delivery, Manufacturing and Packing
Posted: November 6, 2024

Bespak
enquiries@bespak.com

PCI Pharma Services Invests Over $365 Million in EU, US Facilities for Clinical and Commercial Supply of Advanced Drug Delivery and Drug-Device Combination Products

Highlights include investment in Philadelphia biotech facility, acquisition of a new pharma device assembly and packaging facility near Dublin, Ireland, and a new Center of Excellence for advanced drug delivery...

Category: Drug Delivery
Posted: September 25, 2024

PCI Pharma Services
talkfuture@pci.com
3001 Red Lion Road, Philadelphia, PA 19114, USA

Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK

2 September 2024 – Oxford, UK – Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic viral therapies, has been awarded £2M from Innovate UK’s prestigious Transforming Cancer Therapeutics grant funding...

Category: Drug Discovery
Posted: September 5, 2024

Theolytics
enquiries@theolytics.com
The Sherard Building, Edmund Halley Road, Oxford Science Park, Oxford. OX4 4DQ

Pan Cancer T secures €4.25m in Seed Extension Round to advance next-generation T cell therapies

July 11 2024, Rotterdam, the Netherlands – Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25m Seed...

Category: Drug Delivery
Posted: July 11, 2024

Pan Cancer T
rachel.abbott@pancancer-t.com
Marconistraat 16 3029 AK, Rotterdam The Netherlands